In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Prevalence of left ventricular dysfunction in marfan syndrome patients with mild dilated aortic root

Session Poster session 1

Speaker Bashar Ibrahim

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Myocardium
  • Session type : Poster Session
  • FP Number : P186

Authors : B Ibrahim (London,GB), P Poveda (London,GB), M Papadakis (London,GB), S Sharma (London,GB), N Bunce (London,GB), M Tome (London,GB)

Authors:
B Ibrahim1 , P Poveda1 , M Papadakis1 , S Sharma1 , N Bunce1 , M Tome1 , 1St George's University of London, Cardiology Clinical Academic Group, St George's Hospitals NHS Foundation Trust, UK - London - United Kingdom of Great Britain & Northern Ireland ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii146

INTRODUCTION

Cardiovascular manifestations are common in Marfan syndrome (MFS) patients. The presence of cardiomyopathy without significant valve disease or previous aortic or cardiac surgery has been identified before.

Our aim was to investigate the prevalence of Left ventricular disfunction in a selected sub cohort of our MFS patients using cardiac magnetic resonance (CMR).

METHODS

We retrospectively evaluated 90 consecutive patients seen in the Aortopathy clinic who had a CMR. Patient with significant valve dysfunction, previous cardiac or aortic surgery and age =17 years old were excluded. 49 MFS patients who met the Ghent criteria were included. Using CMR Left ventricular (LV) volumes, ejection fraction (EF), stroke volume (SV) and mass were assessed with the standard protocols as well aortic dimensions, presence of valve disease and Late Gadolinium Enhancement (LGE). LV dysfunction was defined as left ventricular ejection fraction =56%.

RESULTS

49 patients were studied, 27 male (55.1%) with a mean population age of 39.9 ± 14 years old. The LV end-diastolic volume (LVEDV) mean was 154.1 ± 36.3 ml with a LVEDV indexed of 78 ± 15.7 ml/m2, LVESV 58.8 ± 18.6 ml, LVESV index 48.5 ± 10 ml/m2, LVEF was 62.8 ± 6.9%, SV 95.77 ± 22.3 ml, SV index 48.5 ± 10 ml/m2, and aortic root diameter was 40 ± 4.7 mm.

LV dysfunction was present in 6 patients (12.2%), which was associated with lower SV and SV index compared with 43 patients (87%) with normal LVEF (SV 71.2 ± 15.5 ml vs 99.3 ± 21.1 ml (p=0.003); SV index 36.7 ± 10.3 ml/m2 vs 50.3 ± 8.7 ml/m2 (p=0.001)). There were no differences found in gender, age, LV or atrial volumes or AoR dimension between the 2 groups.

11 Patients (22.4%) had LVEDV indexed =75th percentile (=182 ml/m2). None of them had LV dysfunction (fig1). Comparing patients with LVEDV indexed =75th percentile to those with <75th percentile the SV was 126.8 ± 10.2ml vs 86.5 ± 15.6ml (p<0.001) and SV indexed was 58.3 ± 6.9 vs 45.46 ± 8.9 ml/m2 (p<0.001) respectively.

CONCLUSION

In our subgroup of MFS with mildly dilated AoR the presence of Left ventricular dysfunction was 12.2%. This was associated with lower SV and SV index. None of the patients with LVEDV indexed =75th percentile (=182 ml/m2) had LVEF dysfunction. No myocardial enhancement was seen in patients who had LGE study.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are